Anthony Hunt - 06 Oct 2026 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Reporting relationship: Director
Issuer ticker: BLFS
Reported as of: 06 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2026, 21:58:14 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Anthony Hunt

Key filing fact

Anthony Hunt filed Form 4 for BIOLIFE SOLUTIONS INC (BLFS) on 08 Oct 2026.

Key facts

This page summarizes Anthony Hunt's Form 4 filing for BIOLIFE SOLUTIONS INC (BLFS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Oct 2026, 21:58.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001606030 Primary reporting owner

Hunt Anthony

Relationship: Director
Address: 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL
Signature: /s/ Anthony Hunt
Signature date: 08 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLFS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -15,046
Change %: -100%
Price
Shares after: 0
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Anthony Hunt is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.